home / stock / lgnd / lgnd news


LGND News and Press, Ligand Pharmaceuticals Incorporated From 03/13/24

Stock Information

Company Name: Ligand Pharmaceuticals Incorporated
Stock Symbol: LGND
Market: NASDAQ
Website: ligand.com

Menu

LGND LGND Quote LGND Short LGND News LGND Articles LGND Message Board
Get LGND Alerts

News, Short Squeeze, Breakout and More Instantly...

LGND - How To Trade (LGND)

2024-03-13 22:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LGND - Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26 th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m...

LGND - Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 23.34% on the day to $91.79. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or a...

LGND - Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Conference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will ho...

LGND - Expected US Company Earnings on Tuesday, February 27th, 2024

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

LGND - Esai gets Japanese approval for epilepsy drug using Ligand technology

2024-02-22 17:03:07 ET More on Ligand Pharmaceuticals Johnson & Johnson posts Q4 beat as pharma and MedTech outperform FDA approves Ligand's Zelsuvmi for treatment of molluscum Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earni...

LGND - Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Fycompa® is the 16 th Captisol-enabled™ product approved worldwide Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour a...

LGND - Trend Tracker for (LGND)

2024-02-21 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LGND - Small cap value stocks with potential M&A candidacy - BofA

2024-02-16 11:10:43 ET More on iShares Russell 2000 ETF: IWM: Technical Analysis Says You Should Buy Small Caps IWM: Supply-Side Disinflation Benefits Small Caps The Most Small-Cap ETFs: Performance, Fundamentals, And Rankings For 102 Funds Investors retract ...

LGND - Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Expansion Deepens Ligand’s Commercial, Clinical and Investment Expertise Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice Presid...

Previous 10 Next 10